Coughlin Timothy 4

What Happened
Timothy Coughlin, a director of Travere Therapeutics (TVTX), exercised 10,000 stock options on 2026-06-12 by paying $26.52 per share (total $265,200). The same day he sold 10,000 shares in an open-market transaction at a weighted average price of $50.0747, generating about $500,747 in proceeds. The Form 4 also reports a related derivative conversion/exercise entry shown at $0 (a technical reporting line tied to the option exercise/settlement).

Key Details

• Transaction date: 2026-06-12; Form 4 filed 2026-06-16 (timely — filed within the required reporting window).
• Option exercise: 10,000 shares exercised at $26.52 per share; total cost $265,200 (Footnote F3: option fully vested).
• Sale: 10,000 shares sold in open market at weighted average $50.0747 (range $50.00–$50.32); proceeds ≈ $500,747 (Footnote F2).
• Sale executed under a written 10b5-1 trading plan adopted 2025-11-19 (Footnote F1).
• The Form shows an additional derivative conversion line at $0 for 10,000 shares — a technical reporting entry related to the exercise/settlement.
• Shares owned after the transactions: not provided in the supplied filing data.

Context
This was an exercise of vested options followed by an immediate open-market sale of the resulting shares — commonly a way for insiders to realize option gains and cover exercise costs. The sell was pre-planned under a 10b5-1 program, which typically makes the sale routine rather than an ad hoc signal of sentiment.